Merger Notification - Announcement according to § 10 Cartel Act
Neopharmed Gentili S.p.A.; BioCryst Ireland Limited
BWB/Z-6999
On 08.07.2025 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Neopharmed Gentili S.p.A., Italy, intends to acquire 100% of the shares in BioCryst Ireland Limited, Ireland ("BioCryst Ireland") from BioCryst Pharmaceuticals Inc ("BioCryst"). BioCryst Ireland and its subsidiaries comprise the European distribution network for BioCryst's ORLADEYO, a prescription medicine, the European rights to which BioCryst will exclusively license to BioCryst Ireland. Neopharmed Gentili S.p.A. is indirectly jointly controlled by Renaissance Partners (Luxembourg), Ardian (France), and Mediolanum Farmaceutici S.p.A. (Italy).
Business Sectors Concerned: pharmaceutical services and products, Manufacture of pharmaceutical preparations.
C - MANUFACTURING C 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations, C 21.2 - Manufacture of pharmaceutical preparations, C 21.20 - Manufacture of pharmaceutical preparations
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 05.08.2025.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 06.08.2025 .